Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amarin Pharmaceuticals Inc.

Division of Valeant Pharmaceuticals International/Amarin Pharmaceuticals Inc.
www.amarinpharma.com

Latest From Amarin Pharmaceuticals Inc.

How Should US FDA Navigate Thorny First Amendment Conundrums: Former Chief Counsels Offer Advice

Daniel Troy suggests FDA increase its investment in science of consumer understanding, while Richard Cooper recommends the "bully pulpit" approach to get industry's attention. A panel of former chief counsels stressed that the agency cannot continue to ignore First Amendment free speech issues.

Advertising, Marketing & Sales Legal Issues

Former US FDA Chief Counsels Offer Advice For Navigating Thorny First Amendment Conundrum

Daniel Troy suggests FDA increase its investment in science of consumer understanding, while Richard Cooper recommends bully pulpit approach to get attention of industry; panel of former chief counsels stresses that agency cannot continue to ignore First Amendment issues.
Advertising, Marketing & Sales Legal Issues

Trump Administration's Rx Drug Price Disclosure Reg Seen As Unworkable

Lawyers say CMS proposed rule requiring TV ads to disclose drug's list price wouldn't survive First Amendment suit and competitors have no reason to try to enforce it.
Pricing Debate Advertising, Marketing & Sales

Advertising Enforcement: US FDA Content To Let Competitors 'Duke It Out,' Woodcock Says

Office of Prescription Drug Promotion is focused on most egregious issues where human safety is at stake; CDER's Woodcock also says that First Amendment issues are affecting enforcement.
Advertising, Marketing & Sales FDA
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Valeant Pharmaceuticals International
  • Senior Management
  • Steve Guillen, VP, Sales & Mktg.
    Michael J Winsor, VP, Fin.
    Bim Strausser, VP, Clinical Dev. & Medical Affairs
    Michael D Coffee, Pres. & COO
  • Contact Info
  • Amarin Pharmaceuticals Inc.
    Phone: (866) 426-2746
    Two Belvedere Pl., Ste. 330
    Mill Valley, CA 94941
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register